Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 175 clinical trials
A Study of PRT1419 Injection in Patients With Relapsed/Refractory Hematologic Malignancies

This is a Phase 1 dose-escalation study of PRT1419, a myeloid cell leukemia 1 (MCL1) inhibitor, in patients with relapsed/refractory hematologic malignancies. The purpose of this study is to define the dosing schedule, maximally tolerated dose and/or estimate the optimal biological dose to be used in subsequent development of PRT1419.

ejection fraction
white blood cell count
leukemia
cancer
leukapheresis
  • 0 views
  • 23 Jul, 2022
  • 7 locations
A Phase 2 Trial of Fractionated Gemtuzumab Ozogamicin to Eradicate Measurable Residual Disease in Acute Myeloid Leukemia Patients (GO for MRD)

This phase II trial studies the how well fractionated gemtuzumab ozogamicin works in treating measurable residual disease in patients with acute myeloid leukemia. Gemtuzumab ozogamicin is a monoclonal antibody, called gemtuzumab, linked to a chemotherapy drug, called ozogamicin. Gemtuzumab is a form of targeted therapy because it attaches to specific …

remission
monoclonal antibodies
tumor cells
blast cells
gemtuzumab ozogamicin
  • 5 views
  • 15 Sep, 2022
  • 1 location
A Phase I/II Study of Recombinant Human Interleukin-7 to Promote T-Cell Recovery After Haploidentical and Cord Blood Stem Cell Transplantation

myeloid leukemia, or myeloproliferative disease after a haploidentical or cord blood stem cell transplant. A haploidentical transplant is a transplant that uses stem cells from a donor that is partially

myeloproliferative disorder
granulocyte colony stimulating factor
filgrastim
myeloid leukemia
chronic myeloid leukemia
  • 0 views
  • 19 Sep, 2022
  • 1 location
Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe) (FluBuBe)

Haploidentical hematopoietic stem cell transplantation irrespective of the conditioning and graft-versus-host disease prophylaxis is associated with high frequency of primary and secondary graft failure. Different technologies of with replete or depleted graft are associated with 10-20% of graft failures. Fludarabine and busulfan conditioning is the most commonly used approach for …

tacrolimus
cell transplantation
hla-a
busulfan
cyclophosphamide
  • 0 views
  • 23 Jul, 2022
  • 1 location
Phase II Study of a Geriatric Assessment-Driven, Risk-Adapted Allogeneic Hematopoietic Cell Transplant Strategy for Older Patients With Myeloid Malignancies

, ,myelodysplastic syndromes, myeloproliferative neoplasms, or related blood disorders who are going to receive chemotherapy or another treatment to prepare the body for an allogeneic hematopoietic stem cell

myelomonocytic leukemia
chronic myelomonocytic leukemia
leukemia
transplant conditioning
myeloid leukemia
  • 0 views
  • 15 Sep, 2022
  • 7 locations
A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT

side effects are seen in patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN), Chronic Myelomonocytic Leukemia (CMML), or Myelofibrosis (MF

myeloproliferative disorder
myelodysplastic/myeloproliferative neoplasms
myelomonocytic leukemia
myelofibrosis
myeloid leukemia
  • 346 views
  • 03 Jul, 2022
  • 2 locations
Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

, myelodysplastic syndrome, chronic myeloid leukemia, and myeloproliferative neoplasms. Chemoprotective drugs, such as dexrazoxane hydrochloride, may protect the heart from the side effects of drugs used in

ejection fraction
cancer chemotherapy
tretinoin
decitabine
blast cells
  • 28 views
  • 23 Mar, 2022
  • 1 location
Randomized Phase 2 Study of CPX-351 + Pomalidomide Versus CPX-351 in Newly Diagnosed AML With MDS-Related Changes

This phase II trial studies the effect of adding pomalidomide to usual chemotherapy treatment (CPX-351) in treating patients with newly diagnosed acute leukemia with myelodysplastic syndrome-related changes. Pomalidomide may stop the growth of blood vessels, stimulate the immune system, and kill cancer cells. Chemotherapy drugs, such as CPX-351, work in …

  • 0 views
  • 22 Sep, 2022
  • 2 locations
CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies

Phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of CLL1-CD33 cCAR in patients with relapsed and/or refractory, high risk hematologic malignancies.

myeloproliferative disorder
graft versus host disease
blast cells
myelodysplastic syndrome with excess blasts-2
stem cell transplantation
  • 16 views
  • 06 Feb, 2022
  • 1 location
Haplo Peripheral Blood Sct In GVHD Prevention

(MDS), myeloproliferative disorders (MPN), chronic myelomonocytic leukemic (CMML), chemosensitive hodgkin lymphoma (HL), or Non-Hodgkin lymphoma (NHL).who will have a blood stem cell transplantation

cell transplantation
ejection fraction
remission
mycophenolate
total body irradiation
  • 0 views
  • 10 Oct, 2021